Obesity , 28 (6), 10501061
2.8% at 24 weeks)
Eli Lilly, which sells Zepbound and Mounjaro, just released a blockbuster Q2 this morning, beating Wall Street projections and raising its 2025 sales guidance
This means the drug does not hit peak levels and stay there permanently
This hormone helps to slow digestion and promote feelings of fullness, which reduces appetite
What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass
